Meta-Analysis of Antibiotics and the Risk of Community-Associated Clostridium difficile Infection

被引:422
作者
Brown, Kevin A. [1 ]
Khanafer, Nagham [2 ]
Daneman, Nick [3 ]
Fisman, David N. [1 ]
机构
[1] Univ Toronto, Div Epidemiol, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada
[2] Univ Lyon, Lab Biometrie & Biol Evolut, Lyon, France
[3] Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Infect Dis, Dept Med, Toronto, ON, Canada
基金
加拿大健康研究院;
关键词
HOSPITAL ADMISSION; EPIDEMIOLOGY; DISEASE; SUSCEPTIBILITY; DIARRHEA; QUALITY;
D O I
10.1128/AAC.02176-12
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The rising incidence of Clostridium difficile infection (CDI) could be reduced by lowering exposure to high-risk antibiotics. The objective of this study was to determine the association between antibiotic class and the risk of CDI in the community setting. The EMBASE and PubMed databases were queried without restriction to time period or language. Comparative observational studies and randomized controlled trials (RCTs) considering the impact of exposure to antibiotics on CDI risk among nonhospitalized populations were considered. We estimated pooled odds ratios (OR) for antibiotic classes using random-effect meta-analysis. Our search criteria identified 465 articles, of which 7 met inclusion criteria; all were observational studies. Five studies considered antibiotic risk relative to no antibiotic exposure: clindamycin (OR = 16.80; 95% confidence interval [95% CI], 7.48 to 37.76), fluoroquinolones (OR = 5.50; 95% CI, 4.26 to 7.11), and cephalosporins, monobactams, and carbapenems (CMCs) (OR = 5.68; 95% CI, 2.12 to 15.23) had the largest effects, while macrolides (OR = 2.65; 95% CI, 1.92 to 3.64), sulfonamides and trimethoprim (OR = 1.81; 95% CI, 1.34 to 2.43), and penicillins (OR = 2.71; 95% CI, 1.75 to 4.21) had lower associations with CDI. We noted no effect of tetracyclines on CDI risk (OR = 0.92; 95% CI, 0.61 to 1.40). In the community setting, there is substantial variation in the risk of CDI associated with different antimicrobial classes. Avoidance of high-risk antibiotics (such as clindamycin, CMCs, and fluoroquinolones) in favor of lower-risk antibiotics (such as penicillins, macrolides, and tetracyclines) may help reduce the incidence of CDI.
引用
收藏
页码:2326 / 2332
页数:7
相关论文
共 36 条
[1]   On logit confidence intervals for the odds ratio with small samples [J].
Agresti, A .
BIOMETRICS, 1999, 55 (02) :597-602
[2]   The distribution of Clostridium difficile in the environment of South Wales [J].
AlSaif, N ;
Brazier, JS .
JOURNAL OF MEDICAL MICROBIOLOGY, 1996, 45 (02) :133-137
[3]   Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish University Hospital [J].
Aspevall, O ;
Lundberg, A ;
Burman, LG ;
Åkerlund, T ;
Svenungsson, B .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (05) :1890-1892
[4]   Clinical and microbiological characteristics of community-onset Clostridium difficile infection in The Netherlands [J].
Bauer, M. P. ;
Veenendaal, D. ;
Verhoef, L. ;
Bloembergen, P. ;
van Dissel, J. T. ;
Kuijper, E. J. .
CLINICAL MICROBIOLOGY AND INFECTION, 2009, 15 (12) :1087-1092
[5]   Risk factors for Clostridium difficile infection [J].
Bignardi, GE .
JOURNAL OF HOSPITAL INFECTION, 1998, 40 (01) :1-15
[6]   Health care-associated pneumonia requiring hospital admission -: Epidemiology, antibiotic therapy, and clinical outcomes [J].
Carratala, Jordi ;
Mykietiuk, Analia ;
Fernandez-Sabe, Nuria ;
Suarez, Cristina ;
Dorca, Jordi ;
Verdaguer, Ricard ;
Manresa, Frederic ;
Gudiol, Francesc .
ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (13) :1393-1399
[7]  
Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P1201
[8]   When can odds ratios mislead? [J].
Davies, HTO ;
Crombie, IK ;
Tavakoli, M .
BRITISH MEDICAL JOURNAL, 1998, 316 (7136) :989-991
[9]   Antimicrobial drugs and community-acquired Clostridium difficile-associated disease, UK [J].
Delaney, J. A. Chris ;
Dial, Sandra ;
Barkun, Alan ;
Suissa, Samy .
EMERGING INFECTIOUS DISEASES, 2007, 13 (05) :761-763
[10]   METAANALYSIS IN CLINICAL-TRIALS [J].
DERSIMONIAN, R ;
LAIRD, N .
CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188